Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer

por Liang, Yuehua, Liu, Xiaoran, Li, Kun, Li, Huiping
Publicado 2022

Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients

por Jiang, Yantao, Zhang, Ju, Zhong, Jianxin, Liao, Hao, Zhang, Jiayang, Liu, Yaxin, Liang, Yuehua, Li, Huiping
Publicado 2023

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients

por Wang, Jinhao, Liu, Yaxin, Liang, Yuehua, Zhang, Yue, Dong, Hang, Zheng, Tiantian, Yu, Jianjun, Du, Pan, Jia, Shidong, King, Bonnie L., Wang, Jing, Liu, Xiaoran, Li, Huiping
Publicado 2023